AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02648529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological assessment
Description: Patients undergo a repeated annual neuropsychological assessment over the five years of their participation in the project.
Study NCT03163862 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Endometrial scratch
Description: the intervention group, endometrial biopsy will be performed with a pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France). The pipelle was introduced gently through the cervix up to the uterine fundus. the examiner applied regular back-and-forth movements (2-4 cm) during a period of 30 s. The obtained specimens will be sent for histology evaluation.
Study NCT03163862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial scratch
Description: the intervention group, endometrial biopsy will be performed with a pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France). The pipelle was introduced gently through the cervix up to the uterine fundus. the examiner applied regular back-and-forth movements (2-4 cm) during a period of 30 s. The obtained specimens will be sent for histology evaluation.
Study NCT03163862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF administration
Description: 1- 300 µg trans cervical intrauterine of G-CSF was administered at the oocyte retrieval day, subcutaneous 300 micrograms G-CSF on the day of embryo transfer
Study NCT03163862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: saline infusion every day from the day of embryo transfer through the day of beta HCG test
Study NCT02974010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-101 Oral Capsule
Description: Prospective Randomized Factorial Design Study as per arm/group descriptions
Study NCT02974010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurasidone Oral Capsule
Description: Prospective Randomized Factorial Design Study as per arm/group descriptions
Study NCT02974010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Intravenous Infusion
Description: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
Study NCT02974010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Intravenous Infusion
Description: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
Study NCT02974010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution Intravenous Infusion
Description: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
Study NCT02974010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution Intravenous Infusion
Description: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
Study NCT02805244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTZ-951, 14C-JTZ-951
Study NCT04590989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Nutrition Plan
Description: * Personalized breakfasts and dinners designed and cooked by Simplefeast, delivered twice a week (eaten 6 days per week) + access to Simplefeast's App for recipes of other meals not provided (i.e. lunches and Saturdays) which are designed to match the individual nutritional recommendations.~* Personalized behavioral change program via electronic push notifications by ONMI
Study NCT04590989 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Personalized Nutrition Plan
Description: * Standard meals of breakfasts and dinners designed and cooked by Simple feast, based on general dietary recommendations, and delivered to participants twice a week. In addition, they will also have access to Simple feast's recipe App for other meals not provided. The recipes presented are generic, not personalized.~* Subjects in the control group will also be enrolled in the behavioral program by ONMI, but the program will not be personalized nor based on the same behavior change methodology as in the PP group. In other words, the control group will get information more than is triggered to take actual action (i.e. general guidelines that is available from the National Health Service and World Health Organization).
Study NCT00647205 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: QuantiFERON TB Gold In-Tube
Study NCT02421016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNERGY EES
Description: Bioresorbable polymer everolimus-eluting stent
Study NCT02421016 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABSORB [BVS]
Description: Everolimus-eluting bioresorbable backbone stent
Study NCT00792441 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: intervention group
Description: inspiratory muscle training at 50% of peak negative inspiratory muscle training (PNIP)will be performed with 6 breathe/set, 10 set/day, once a day for 28 days.
Study NCT04347330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive BP Control
Description: Participants in the Intensive group have a goal of home SBP \<120 mm Hg. The CRAFT BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications, but there should be preferences among the drug classes, based on CVD outcome trials results and current guidelines. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. Combination of different classes of agents are encouraged to achieve the home SBP goal. Medications will not be provided by the CRAFT study.
Study NCT04347330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard BP Control
Description: Participants in the Standard group has a goal of home SBP \<135 mmHg. The same principle of BP treatment in the Intensive BP arm will be used for the Standard BP arm. Medications will not be provided by the CRAFT study.
Study NCT01417351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 400 IU vitamin D3
Description: Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
Study NCT01417351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2,000 IU Vitamin D3
Description: Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
Study NCT03398590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-regulation theory-based mHealth behavior intervention
Description: Participants will receive a self-regulation theory-based mHealth behavior intervention (5 biweekly group sessions, 60 minutes /session). An experienced Certified Diabetes Educator from the Joslin Diabetes Center and PI (Dr. Zheng) who has been trained using self-regulation for weight loss will co-facilitate group sessions. The intervention combines diet modification and increased physical activity with a weekly weight loss goal as well as focuses on improving participants' three typical self-regulation strategies - self-monitoring, self-evaluation and self-reinforcement. Intervention duration will last 2 months with subsequent 1-month follow.
Study NCT01540292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSC)
Description: MSC (1.5-2 cells/kg BW) IV injection, twice at 4 weeks apart
Study NCT00736398 — intervention group
Intervention type: PROCEDURE
Intervention: Spinal fusion
Description: Spinal fusion
Study NCT02625506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine
Description: Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine
Study NCT02625506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine and Tramadol
Description: Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine in conjunction with tramadol
Study NCT03319069 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Hypofractionated radiotherapy 43,5 GY/15 fractions (f)/3ws. to chest wall and supraclavicular nodal region.~.
Study NCT03319069 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fractionated radiotherapy
Description: 50 Gray(GY)/ 25f/5 weeks(5w) to chest wall and supraclavicular nodal region
Study NCT02426541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
Study NCT02426541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
Study NCT02031237 — intervention group
Intervention type: RADIATION
Intervention: Single Fraction Stereotactic Radiosurgery (SRS)
Description: Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
Study NCT02031237 — intervention group
Intervention type: RADIATION
Intervention: Fractionated Whole Brain Radiation Therapy (WBRT)
Description: Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
Study NCT02031237 — intervention group
Intervention type: RADIATION
Intervention: Fractionated Stereotactic Radiation Therapy (FSRT)
Description: Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
Study NCT02031237 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging (MRI) Assessments
Description: MRI scans will include a routine clinical MRI series.
Study NCT02317250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amyloid imaging
Description: Amyloid imaging brain scans are administered once to all arms.
Study NCT02317250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amyloid imaging
Description: Amyloid imaging brain scans are administered once to all arms.
Study NCT02317250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FDG-PET
Description: \[F-18\] FDG-PET brain scans are administered once to all arms.
Study NCT02317250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: \[F-18\] FDG-PET brain scans are administered once to all arms.
Study NCT04847999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark chocolate
Description: Dark chocolate
Study NCT01110317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate 100 mg
Description: Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1, 8, 36, and 64.
Study NCT02145624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repevax
Description: vaccine
Study NCT02145624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix-IPV
Description: vaccine
Study NCT02851732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Improvement Intervention
Description: The quality improvement intervention includes case management, reminders, check lists, educational materials, and audit and feedback reports
Study NCT01071031 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-v (Low Dose)
Description: Low Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences) with water for injection or adjuvant~Administration: A single subcutaneous injection
Study NCT01071031 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-v (High Dose)
Description: High Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences with water for injection or adjuvant~Administration: A single subcutaneous injection
Study NCT01071031 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HIV-v (Control)
Description: Adjuvant only or Water for injection only~Administration: A single subcutaneous injection
Study NCT00697801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 low dose
Description: a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
Study NCT00697801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 high dose
Description: a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
Study NCT00697801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo delivered by nebulization twice daily for 6 weeks
Study NCT03886649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The only dose level 1 (DL1) is 60 mg copanlisib.
Study NCT03886649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The starting dose is dose level 1 (DL1): 600 mg venetoclax.
Study NCT02463838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Support Intervention
Description: Case management and care coordination intervention delivered in person to SFHP members who are frequent users of emergency department and inpatient hospital services.
Study NCT03371329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: bone marrow derived cultured MSC (mesenchymal stem cell)
Study NCT00647205 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: T-SPOT.TB®
Study NCT01909232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
Description: The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the active group, magnetic power output will be delivered to the subject through the coils.
Study NCT01909232 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
Description: The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
Study NCT02577484 — intervention group
Intervention type: DEVICE
Intervention: RXi System
Description: Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.~Measurement of FFR requires simultaneously monitoring the blood pressures proximal and distal to a lesion. The RXi system includes a single use catheter (Navvus) with a pressure sensor for acquisition of the distal pressure. The proximal pressure is acquired by the guide catheter via an interface to the hospital hemodynamic monitor.~The Navvus catheter interfaces to the RXi system console which includes embedded software, a user interface touch screen and associated electronics.
Study NCT02577484 — intervention group
Intervention type: DEVICE
Intervention: Pressure Wire
Description: Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.
Study NCT01178762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
Study NCT02377362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLWL-01, Part A
Description: Capsules administered orally, in 2 out of 3 periods
Study NCT02377362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Part A
Description: Capsules administered orally in 1 out of 3 periods
Study NCT02377362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLWL-01, Part B
Description: Capsules administered orally either once or twice daily for 27 days, with a single dose on Day 28
Study NCT02377362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Part B
Description: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
Study NCT02377362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLWL-01, Part C
Description: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
Study NCT02377362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Part C
Description: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
Study NCT00409058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Online Problem Solving
Description: We will test the following hypotheses: 1) Children with TBI receiving TOPS will have fewer behavior problems, greater social competence, and better functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 2) Caregivers of children receiving TOPS will report less depression and psychological distress, less parent-child conflict, and better family functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 3) Social resources will moderate treatment efficacy, such that children with limited social and economic resources will show greater improvements in the more comprehensive TOPS intervention. We hypothesize better teen problem solving and communication skills, fewer teen emotional/behavioral problems, less parental burden and distress, and less parent-teen conflict at follow-up among the TOPS group compared to the IRC group.
Study NCT01819038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous renal replacement therapy
Study NCT01482273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CDT+US group
Description: CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
Study NCT01482273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CDT-US group
Description: CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
Study NCT01238354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: With friend
Study NCT01238354 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Without friend
Study NCT02280070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory test
Description: Leukocyte, neutrophil (ANC ：stab + seg), hemoglobin, platlet, albumin, total birrilubin, AST, ALT, LDH, Creatinine, Na, K, CRP, fast blood sugar
Study NCT01819038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous renal replacement therapy
Study NCT01723436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothetical scenarios and related decisions
Description: Surrogates are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
Study NCT01003015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY73-4506
Description: 160 mg BAY73-4506
Study NCT03787875 — intervention group
Intervention type: PROCEDURE
Intervention: periodontal treatment
Description: In the study group, periodontal scaling and root planning treatment of the 4 quadrants was performed for two consecutive weeks without the use of antiseptics or antibiotics, and the patients were instructed in oral hygiene, including both brushing techniques and proximal hygiene.
Study NCT01638624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol :Propofol is an anesthetic agent, has structure similar to that of known such as alfa tocopherol.
Study NCT01638624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01513642 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Breath Stacking
Description: To perform the BS maneuver, a silicone mask containing a one-way valve was attached to the patient's face. Once the mask was adjusted to allow only inspiration (the expiratory branch remained occluded), the patient was asked to make successive inspiratory efforts during 20 seconds.
Study NCT02896894 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Big White Wall (BWW)
Description: The BWW is an internet-based intervention that incorporates several elements of mental health care that have been shown to be effective, in a virtual environment that provides anonymity (see www.bigwhitewall.com). The on-line portal gives users access to self-assessment tools to track symptoms for a wide range of conditions over time, educational materials, a social network that allows communication between people who may have similar problems, and access to on-line courses. The service is monitored at all times by Wall Guides to ensure that users are responded to and that the content posted is appropriate and safe.
Study NCT02896894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Big White Wall (BWW)
Description: The BWW is an internet-based intervention that incorporates several elements of mental health care that have been shown to be effective, in a virtual environment that provides anonymity (see www.bigwhitewall.com). The on-line portal gives users access to self-assessment tools to track symptoms for a wide range of conditions over time, educational materials, a social network that allows communication between people who may have similar problems, and access to on-line courses. The service is monitored at all times by Wall Guides to ensure that users are responded to and that the content posted is appropriate and safe.